Study of KY-0301 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called KY-0301 for people with advanced solid tumors that have not responded to standard treatments. The study has two parts: Part I includes various solid tumor types, while Part II focuses on specific cancers like non-small cell lung cancer or colorectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a locally advanced or metastatic solid tumor that has not responded to standard treatments.
- You must have a body weight of at least 45 kg for women or 50 kg for men, with a BMI of 18 or higher.
- You cannot have had severe side effects from similar antibody-drug therapies.
- You cannot have untreated or active brain metastases or certain heart, lung, or gut conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new cancer treatment (YKYY031) given by injection for advanced colorectal or pancreatic cancer that has stopped responding to standard treatments. The drug is designed to target specific genetic changes (mutations) found in some tumors, and your immune system must match a particular genetic marker (HLA-A*11:01) for the drug to work.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This trial tests an experimental drug, TYK-01054, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or control the cancer.
This study tests a new drug, KC1086, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to find out if KC1086 is safe and possibly effective, and it may be an option if you are physically active and your organs are healthy.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.